Traders should anticipate significant near-term downside pressure due to dilution; the contingent second tranche introduces additional uncertainty tied to stock performance, creating a negative feedback loop. Monitor SEC filings for final prospectus and actual share counts. Warrant overhang (150% coverage) and low exercise prices may suppress upside even if fundamentals improve.
Price Chart
Executive Summary
VivoSim Labs announced the pricing of a $4 million best-efforts public offering, with $3 million expected at an initial closing and $1 million contingent on future conditions including minimum stock price and trading volume. The offering includes common stock, pre-funded warrants, and common warrants with immediate exercisability, led by a single family office and facilitated by Joseph Gunnar & Co. as placement agent.
Key Financial Metrics
Key Facts
- VivoSim Labs is raising up to $4 million in a best-efforts public offering.
- $3 million is expected at the initial closing on April 1, 2026, with $1 million contingent on future conditions including minimum closing price and average trading volume.
- Initial Closing involves issuance of 286,557 common shares and 2,345,022 pre-funded warrants at $1.140/share and $1.139/warrant, respectively.
- Common warrants for 150% of shares sold (3,947,369) are being issued with an exercise price of $1.710, exercisable immediately, expiring in five years.
- Prefunded warrants have a nominal exercise price of $0.001 and expire upon full exercise.
- The offering is being made via an effective S-1 registration statement, with final prospectus to be filed.
- The company has a market cap of only $4 million, meaning this offering could result in massive near-term dilution.
Financial Impact
Up to $4 million in new capital, but with extreme dilution risk: pro forma share count could increase by over 200% assuming full exercise of warrants and second tranche.
Risk Factors
- Extreme dilution: warrants cover 150% of shares issued, and prefunded warrants are nearly free to exercise.
- Second tranche is contingent on stock price and volume, which may not be met, signaling weak investor confidence.
- Market cap is only $4 million — this offering represents 100% of current equity value, increasing supply dramatically.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3266585 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 9d ago | 8-K | $0.1575 | awaiting T+20 | — | $0.1483 (+5.84%) |
Oct 6, 2026 19d ago | 8-K | $0.1915 | awaiting T+20 | — | $0.1483 (−22.56%) |
Sep 16, 2026 5w ago | Press Release | $0.2621 $0.1742 | ▼ −33.54% | ▼ −36.71% | $0.1483 (−43.42%) |
Aug 11, 2026 10w ago | EFFECT | $0.3526 $0.2750 | ▲ +22.01% | ▲ +20.95% | $0.1483 (+57.94%) |
Aug 6, 2026 11w ago | 8-K | $0.3299 $0.2790 | ▼ −15.43% | ▼ −16.03% | $0.1483 (−55.05%) |
Jul 17, 2026 14w ago | 8-K | $0.5790 $0.3225 | ▲ +44.30% | ▲ +48.75% | $0.1483 (+74.39%) |
Apr 3, 2026 29w ago | 8-K | $1.71 $1.41 | ▼ −17.54% | ▼ −26.53% | $0.1483 (−91.33%) |
Apr 1, 2026 29w ago | Press Release | $1.62 $1.44 | ▲ +11.11% | ▲ +20.83% | $0.1483 (+90.85%) |
Apr 1, 2026 29w ago | EFFECT | $1.62 $1.44 | ▼ −11.11% | ▼ −20.83% | $0.1483 (−90.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers